Armistice Capital’s BioNTech BNTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$16.1M Buy
+164,000
New +$15.9M 0.2% 74
2023
Q2
– Sell
-36,000
Closed -$4.48M – 229
2023
Q1
$4.48M Sell
36,000
-4,000
-10% -$549K 0.06% 109
2022
Q4
$6.01M Sell
40,000
-116,000
-74% -$17.9M 0.1% 91
2022
Q3
$21M Buy
156,000
+56,000
+56% +$8.56M 0.37% 58
2022
Q2
$14.9M Buy
100,000
+25,000
+33% +$3.82M 0.26% 70
2022
Q1
$12.8M Buy
75,000
+7,000
+10% +$1.18M 0.25% 68
2021
Q4
$17.5M Buy
68,000
+16,000
+31% +$4.38M 0.29% 77
2021
Q3
$14.2M Sell
52,000
-12,000
-19% -$3.81M 0.24% 78
2021
Q2
$14.3M Sell
64,000
-212,000
-77% -$40M 0.26% 79
2021
Q1
$30.1M Buy
276,000
+40,000
+17% +$4.25M 0.69% 42
2020
Q4
$19.2M Sell
236,000
-100,000
-30% -$9.8M 0.65% 45
2020
Q3
$23.3M Buy
+336,000
New +$24.1M 0.84% 44

Other funds holding BNTX

Armistice Capital's BNTX Position: Q3 2026 in Review

Armistice Capital opened a new position in BioNTech (BNTX) in Q3 2026: 164,000 shares worth $16.1M. The stake represents 0.2% of the portfolio and ranks #74 among its holdings. This is a return to the name: Armistice Capital previously reported a position in BNTX as recently as Q1 2023.

Armistice Capital first reported a position in BNTX in Q3 2020 and has held it in 12 quarters since. The position peaked at $30.1M in Q1 2021. 302 funds tracked by Wall St. Rank hold BNTX as of Q3 2026.

  • Armistice Capital held 164,000 shares of BioNTech worth $16.1M as of Q3 2026.
  • BioNTech was a new Armistice Capital position in Q3 2026.
  • BioNTech made up 0.2% of Armistice Capital's portfolio in Q3 2026, its #74 holding.
  • Armistice Capital first reported a position in BioNTech in Q3 2020 and has held it in 12 quarters since.
  • Armistice Capital's BioNTech position peaked at $30.1M in Q1 2021.
  • 302 funds tracked by Wall St. Rank held BioNTech as of Q3 2026.

Based on Armistice Capital's 13F filing for Q3 2026, filed 16 Nov 2026.